Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling

References

• Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:442-50
   PubMed Web of Science ®Google Scholar
• Guide to the methods of technology appraisal 2013. London: National Institute for Health and Care Excellence (NICE), 2013. http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. Accessed January 10, 2014
   Google Scholar
• Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 2nd edn. Oxford: Oxford University Press, 1997
   Google Scholar
• Purchasing power parities (PPPs) data. Paris: Organisation for Economic Co-operation and Development (OECD), 2012. http://www.oecd.org/document/47/0,3746,en_2649_34347_36202863_1_1_1_1,00.html. Accessed January 10, 2014
   Google Scholar
• Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, 2012. http://www.pssru.ac.uk/project-pages/unit-costs/2012/. Accessed January 10, 2014
   Google Scholar
• O’Reilly D, Hopkins R, Blackhouse G, et al. Development of an Ontario Diabetes Economic Model (ODEM) and application to a multidisciplinary primary care diabetes management program. Hamilton, ON: Program for Assessment of Technology in Health (PATH), 2006. http://www.path-hta.ca/Libraries/Reports/Development_of_an_Ontario_Diabetes_Economic_Model_ODEM_and_Application_to_a_Multidisciplinary_Primary_Care_Diabetes_Management_Program.sflb.ashx. Accessed January 10, 2014
   Google Scholar
• Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007;25:253-66
   PubMed Web of Science ®Google Scholar
• Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. Can Med Assoc J 2009;180:400-7
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweiz Med Wochenschr 2000;130:1034-40
   PubMedGoogle Scholar
• Brändle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther 2011;49:217-30
   PubMed Web of Science ®Google Scholar
• Woehl A, Evans M, Tetlow AP, et al. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom (structured abstract). Cardiovasc Diabetol 2008;7:24
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) (structured abstract). Diabetologia 2005;48:868-77
   PubMed Web of Science ®Google Scholar
• Ly D, Fu AZ, Hebert C. Cost effectiveness analysis of a hypertension management program in patients with type 2 diabetes (structured abstract). J Clin Hypertens 2009;11:116-24
   PubMed Web of Science ®Google Scholar
• Neeser K, Weber C. Cost impact of self-measurement of blood glucose on complications of type 2 diabetes: the Spanish perspective. Diabetes Technol Ther 2009;11:509-16
   PubMedGoogle Scholar
• O’Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-38
   PubMed Web of Science ®Google Scholar
• Cameron C, Coyle D, Ur E, et al. Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin (structured abstract). CMAJ 2010;182:28-34
   PubMed Web of Science ®Google Scholar
• Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2002;20(1 Suppl):31-42
   Google Scholar
• Roze S, Valentine WJ, Evers T, et al. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting (structured abstract). Curr Med Res Opin 2006;22:1415-24
   PubMed Web of Science ®Google Scholar
• Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy 2010;8:191-202
   PubMedGoogle Scholar
• Goodall G, Jendle JH, Valentine WJ, et al. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. Int J Clin Pract 2008;62:869-76
   PubMed Web of Science ®Google Scholar
• Lindgren P, Lindstrom J, Tuomilehto J, et al. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care 2007;23:177-83
   PubMed Web of Science ®Google Scholar
• Brändle M, Erny-Albrecht KM, Goodall G, et al. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther 2009;47:501-15
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Bottomley JM, Palmer AJ, et al. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK (structured abstract). Diabetic Med 2007;24:982-1002
   PubMed Web of Science ®Google Scholar
• Li R, Zhang P, Barker LE, et al. Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. Diabetes Care 2010;33:1193-9
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Clarke LD, Roberts CS, et al. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmacoeconomics 2008;26:329-39
   PubMed Web of Science ®Google Scholar
• Weber C, Kocher S, Neeser K, et al. Impact of self-measurement of blood glucose on complications of type 2 diabetes: Economic analysis from a Czech perspective. Curr Med Res Opin 2010;26:289-96
   PubMed Web of Science ®Google Scholar
• Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes (structured abstract). Curr Med Res Opin 2007;23:609-22
   PubMed Web of Science ®Google Scholar
• Maetzel A, Ruof J, Covington M, et al. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus (structured abstract). Pharmacoeconomics 2003;21:501-12
   PubMed Web of Science ®Google Scholar
• Ray JA, Valentine WJ, Roze S, et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs insulin glargine in the US (structured abstract). Diabetes Obes Metab 2007;9:103-13
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Goodall G, Aagren M, et al. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Adv Ther 2008;25:567-84
   PubMed Web of Science ®Google Scholar
• Herman WH, Thomas MP, Hoerger TJ, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance (structured abstract). Ann Intern Med 2005;142:323-32
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Palmer AJ, Lammert M, et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting (structured abstract). Curr Med Res Opin 2005;21:2063-71
   PubMed Web of Science ®Google Scholar
• Hayashino Y, Nagata-Kobayashi S, Morimoto T, et al. Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with type 2 diabetes and additional atherogenic risk factors. J Gen Intern Med 2004;19:1181-91
   Google Scholar
• Marissal JP, Gueron B, Dervaux B. The cost of complications: implications for the measurement of the cost of type II diabetes mellitus. Rev Epidemiol Sante Publ 2006;54:137-47
   Google Scholar
• Liebl A, Spannheimer A, Reitberger U, et al. Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2(registered trademark) study. Med Klin 2002;97:713-19
   Google Scholar
• Lucioni C, Mazzi S, Neeser K. Cost-effectiveness analysis of pioglitazone therapy in DMT2. Pharmaco Econ Ital Res Artic 2004;6:81-93
   Google Scholar
• Ringborg A, Yin DD, Martinell M, et al. The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden. Eur J Cardiovasc Prev Rehabil 2009;16:576-82
   PubMed Web of Science ®Google Scholar
• Grzeszczak W, Czupryniak L, Kolasa K, et al. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technol Ther 2012;14:65-73
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford: Oxford University Press, 2005
   Google Scholar
• O’Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003;3:7
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Caro I, Getsios D, et al. Diabetes in Canada: direct medical costs of major macrovascular complications. Value Health 2001;4:258-65
   Google Scholar
• Saric T, Benkovic V, Poljicanin T, et al. Cost of diabetes in Croatia impact of complications on the costs of type II diabetes. Madrid: International Society of Pharmacoeconomics and Outcomes Research 14th Annual European Congress, 2011. Abstract and poster 27649
   Google Scholar
• Marissal JP, Sailly JC, Crainich D, et al. Évaluation de l’impact budgétaire de l’application des recommendations de bonne pratique dans le diabète de type II en France. Rev Epidemiol Sante Publique 2005;53:1567-78
   Google Scholar
• Ramsey SD, Newton K, Blough D, et al. Patient-level estimates of the cost of compliucationsin diabetes in a managed-care population. Pharmacoeconomics 1999;16:285-95
   PubMed Web of Science ®Google Scholar
• Weber C, Neeser K, Wenzel H, et al. Cost of type 2 diabetes in Germany over 8 years: the Rosso study no. 2. J Med Econ 2006;9:45-53
   Google Scholar
• Meléndez G, Cabra HA, Zanela OO, et al. Cost of type 2 diabetes complications in Mexico. Rio de Janeiro: International Society of Pharmacoeconomics and Outcomes Research 2nd Latin America Conference, 2009. Abstract and poster 21971
   Google Scholar
• Weber C, Schneider B, Lodwig V, et al. Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No. 11). Swiss Med Wkly 2007;137:545-50
   PubMedGoogle Scholar